Option chain shows key data for Lucid Diagnostics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Lucid Diagnostics.

Lucid Diagnostics (NASDAQ:LUCD) Stock, Option Chain

Lucid Diagnostics

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Doctor,Utilizing,Advanced,Digital,Tablet,Technology,In,Modern,Healthcare.,Medical

Analyst Color

Long Ideas

News

Health Care

Reiteration

Analyst Ratings

Movers

Trading Ideas

LUCD

A Needham analyst predicts that Lucid Diagnostics (NASDAQ: LUCD) will see a surge in testing volumes with expected Medicare reimbursement approval.

Lucid Diagnostics: DNA Testing To Get Medicare Coverage, Driving Volumes, Says Bullish Analyst

What Happened

Price Target

Markets

BIOA

CART

CVNA

TSLA

VRSN

Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday

Biotech

Financial Advisors

Penny Stocks

Small Cap

Management

Tech

Personal Finance

General

ALUR

GEVO

KULR

Most investors&#39; definition of a penny stock has broadened to include not just companies trading at less than $1 per share, but also those with slightly higher stock prices up to about $5 per share. Regardless of your exact threshold, these firms remain a high-risk, high-reward proposition.

October&#39;s 4 Best Penny Stocks: High-Risk, High-Reward Picks

Lucid Diagnostics Inc

Press Releases

Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

Earnings

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology

Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Offerings

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

PAVM

Accuray

Anteris Technologies Global Corp. - Common Stock

Anteris Technologies

BrainsWay Ltd. - American Depositary Shares

BrainsWay

CytoSorbents

CVRx

Alpha Tau Medical

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Edap TMS

Electromed

Fonar

Inogen

Kewaunee Scientific Corporation - Common Stock

Kewaunee Scientific

KORU Medical Systems, Inc. - Common Stock

KORU Medical Systems

LENSAR

Microbot Medical

Monogram Technologies Inc. - Common Stock

Monogram Technologies

Milestone Scientific

Myomo

Orchestra BioMed Holdings, Inc. - Ordinary Shares

Orchestra BioMed Hldgs

Odysight ai

Outset Medical

Sight Sciences

Sensus Healthcare

Stereotaxis

JIN MEDICAL INTERNATIONAL LTD. - Ordinary Shares

Jin Medical International

Zynex

Ascendiant Capital

Needham

Cantor Fitzgerald

Canaccord Genuity

Comments

Lucid Diagnostics

Lucid Diagnostics (LUCD) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell